ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CERE Cerevel Therapeutics Holdings Inc

42.125
-0.015 (-0.04%)
Last Updated: 12:49:52
Delayed by 15 minutes

Period:

Draw Mode:

Volume 239,068
Bid Price 42.12
Ask Price 42.13
News -
Day High 42.19

Low
19.59

52 Week Range

High
43.5898

Day Low 42.00
Company Name Stock Ticker Symbol Market Type
Cerevel Therapeutics Holdings Inc CERE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.015 -0.04% 42.125 12:49:52
Open Price Low Price High Price Close Price Prev Close
42.01 42.00 42.19 42.14
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,294 239,068 $ 42.10 $ 10,065,553 - 19.59 - 43.5898
Last Trade Time Type Quantity Stock Price Currency
12:50:34 96 $ 42.12 USD

Cerevel Therapeutics Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.83B 181.58M - 0 -432.84M -2.38 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cerevel Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CERE Message Board. Create One! See More Posts on CERE Message Board See More Message Board Posts

Historical CERE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week42.0242.2141.18541.741,419,7060.1050.25%
1 Month42.3042.6041.18542.091,195,418-0.175-0.41%
3 Months42.1143.589840.6641.981,451,0860.0150.04%
6 Months23.6643.589822.1539.432,016,53118.4778.04%
1 Year26.3043.589819.5935.981,365,67315.8360.17%
3 Years15.5446.160812.0131.96959,22626.59171.07%
5 Years10.4546.16089.0031.15871,50731.68303.11%

Cerevel Therapeutics Description

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Your Recent History

Delayed Upgrade Clock